BridgeBio Pharma Inc. (NASDAQ:BBIO) went up by 11.38% from its latest closing price compared to the recent 1-year high of $12.64. The company’s stock price has collected 9.33% of gains in the last five trading sessions. Barron’s reported on 12/28/21 that BridgeBio Rallies After Its Worst Trading Day. Stocktwits Mentions Are Rising.
Is It Worth Investing in BridgeBio Pharma Inc. (NASDAQ :BBIO) Right Now?
Plus, the 36-month beta value for BBIO is at 0.62. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for BridgeBio Pharma Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $22.11, which is $12.18 above the current price. BBIO currently public float of 107.05M and currently shorts hold a 17.75% ratio of that float. Today, the average trading volume of BBIO was 1.24M shares.
BBIO’s Market Performance
BBIO stocks went up by 9.33% for the week, with a monthly jump of 14.89% and a quarterly performance of -9.01%, while its annual performance rate touched -7.86%. The volatility ratio for the week stands at 7.21% while the volatility levels for the past 30 days are set at 8.51% for BridgeBio Pharma Inc. The simple moving average for the period of the last 20 days is 20.28% for BBIO stocks with a simple moving average of 1.79% for the last 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with SVB Leerink repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to SVB Leerink is $24 based on the research report published on December 27th of the previous year 2021.
Mizuho, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $25, previously predicting the price at $86. The rating they have provided for BBIO stocks is “Buy” according to the report published on December 27th, 2021.
BofA Securities gave a rating of “Buy” to BBIO, setting the target price at $75 in the report published on September 10th of the previous year.
BBIO Trading at 9.13% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.91% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 7.21%, as shares surge +14.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.04% upper at present.
During the last 5 trading sessions, BBIO rose by +9.33%, which changed the moving average for the period of 200-days by -21.83% in comparison to the 20-day moving average, which settled at $7.95. In addition, BridgeBio Pharma Inc. saw 24.54% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BBIO starting from STEPHENSON BRIAN C, who sale 61,040 shares at the price of $7.67 back on Jan 05. After this action, STEPHENSON BRIAN C now owns 280,224 shares of BridgeBio Pharma Inc., valued at $468,470 using the latest closing price.
Kumar Neil, the CEO and President of BridgeBio Pharma Inc., sale 120,000 shares at $7.67 during a trade that took place back on Jan 05, which means that Kumar Neil is holding 1,492,722 shares at $920,856 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -827.12 for the present operating margin
- +90.88 for the gross margin
The net margin for BridgeBio Pharma Inc. stands at -806.90. Equity return is now at value 48.20, with -57.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.